Literature DB >> 19043743

The role of methadone in opioid rotation-a Polish experience.

Wojciech Leppert1.   

Abstract

BACKGROUND: To assess methadone analgesia, adverse effects, and calculation method of equianalgesic doses with oral morphine.
MATERIALS AND METHODS: Methadone was administered to 21 opioid-tolerant cancer patients because of pain (numerical rating scale [NRS] > 5) on morphine (ten patients), transdermal fentanyl (TF; four patients), morphine, ketamine, and TF (one patient), tramadol (one patient), pethidine (one patient), pain with drowsiness on morphine with ketamine (three patients), and pain with nausea on morphine (one patient). Dose ratios of equivalent daily dose of oral morphine (ddom) to daily dose of oral methadone (ddomet) were 4:1 (ddom to 100 mg), 6:1 (101-300 mg), 12:1 (301-1,000 mg), and 20:1 (over 1,000 mg). Previous opioid treatment was stopped completely (stop-start approach) in 19 patients; two received methadone and other opioids. The mean ddom before switch was 812 +/- 486 mg. Methadone was administered regularly three times daily; 20 patients received oral methadone, one patient received rectal suppositories. Breakthrough pain was treated with methadone (half of regular dose), morphine, fentanyl, metamizol, ketoprofen, or ketamine.
RESULTS: Mean time of methadone treatment was 38.3 +/- 27.1 days (range 3-95 days), mean daily doses: start 48.1 +/- 19.7 mg, maximal 148.5 +/- 104.1 mg, treatment completion 131.1 +/- 104.3 mg. Good analgesia (NRS < 4) was observed in 11 patients, partial (NRS 4-5) in nine patients, and unsatisfactory (NRS > 5) in one patient. Adverse effects such as drowsiness (six patients), constipation (six patients), nausea and vomiting (two patients), sweating (two patients), and respiratory depression (one patient) the last one resolved by methadone cessation and naloxone.
CONCLUSIONS: Results confirmed high analgesic efficacy, acceptable methadone adverse event profile, safety, and effectiveness of ddom to ddomet dose calculation method.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043743     DOI: 10.1007/s00520-008-0537-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  40 in total

1.  Parenteral methadone: an essential medication for the treatment of pain.

Authors:  Paolo L Manfredi; Kathleen M Foley; Richard Payne; Raymond Houde; Charles E Inturrisi
Journal:  J Pain Symptom Manage       Date:  2003-08       Impact factor: 3.612

2.  Methadone: an orphan drug?

Authors:  Carla Ripamonti; Mauro Bianchi; Eduardo Bruera
Journal:  J Palliat Med       Date:  2004-02       Impact factor: 2.947

Review 3.  Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration.

Authors:  M P Davis; D Walsh
Journal:  Support Care Cancer       Date:  2001-03       Impact factor: 3.603

4.  Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations.

Authors:  S Watanabe; M Belzile; N Kuehn; J Hanson; E Bruera
Journal:  Cancer Treat Rev       Date:  1996-01       Impact factor: 12.111

5.  Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.

Authors:  E Bruera; J Pereira; S Watanabe; M Belzile; N Kuehn; J Hanson
Journal:  Cancer       Date:  1996-08-15       Impact factor: 6.860

Review 6.  A systematic review of opioid conversion ratios used with methadone for the treatment of pain.

Authors:  Douglas J Weschules; Kevin T Bain
Journal:  Pain Med       Date:  2008-06-28       Impact factor: 3.750

Review 7.  Adjuvant analgesics in cancer pain management.

Authors:  David Lussier; Angela G Huskey; Russell K Portenoy
Journal:  Oncologist       Date:  2004

8.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

9.  A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.

Authors:  Roelien H Enting; Wendy H Oldenmenger; Carin C D van der Rijt; Erik B Wilms; Erna J Elfrink; Ineke Elswijk; Peter A E Sillevis Smitt
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

10.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.

Authors:  E E Codd; R P Shank; J J Schupsky; R B Raffa
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

View more
  5 in total

Review 1.  Pharmacological options for the management of refractory cancer pain-what is the evidence?

Authors:  B Afsharimani; K Kindl; P Good; J Hardy
Journal:  Support Care Cancer       Date:  2015-03-07       Impact factor: 3.603

2.  Pharmacology of nonsteroidal antiinflammatory drugs and opioids.

Authors:  Dick Slater; Sushama Kunnathil; Joseph McBride; Rajah Koppala
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

3.  Continuing methadone for pain in palliative care.

Authors:  Philippa Hawley; Ryan Liebscher; Jessica Wilford
Journal:  Pain Res Manag       Date:  2013 Mar-Apr       Impact factor: 3.037

4.  Reporting characteristics of cancer pain: a systematic review and quantitative analysis of research publications in palliative care journals.

Authors:  Senthil P Kumar
Journal:  Indian J Palliat Care       Date:  2011-01

Review 5.  Toward a systematic approach to opioid rotation.

Authors:  Howard S Smith; John F Peppin
Journal:  J Pain Res       Date:  2014-10-17       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.